The Goldman Sachs Group Boosts Agios Pharmaceuticals (NASDAQ

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) had its price target upped by The Goldman Sachs Group from $29.00 to $33.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price suggests a potential downside of 4.29% from […]

Related Keywords

Canada , United States , James William Burns , Zurcher Kantonalbank Zurich Cantonalbank , Jacqualyna Fouse , Goldman Sachs Group , Agios Pharmaceuticals Inc , Mirae Asset Global Investments Co , Securities Exchange Commission , Cantor Fitzgerald , Agios Pharmaceuticals Price Performance , Royal Bank , News Ratings For Agios Pharmaceuticals Daily , Jpmorgan Chase Co , Institutional Trading Of Agios Pharmaceuticals , Td Asset Management Inc , Sg Americas Securities , Agios Pharmaceuticals , Get Free Report , Exchange Commission , Director Jacqualyn , Kantonalbank Zurich Cantonalbank , Asset Global Investments , Management Inc , Agios Pharmaceuticals Daily , Nasdaq Agio , Plagio , Medical , Boost Price Target , The Goldman Sachs Group Inc ,